US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAIA Biotechnology Inc.

2.10

+0.05002.44%

Post-market: 2.02-0.0800-3.81%19:56 EDT

Volume:238.48K

Turnover:477.01K

Market Cap:62.13M

PE:-2.00

High:2.10

Open:2.05

Low:1.90

Close:2.05

Loading ...

Overview Company News Filings

BRIEF-MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval

Maia Biotechnology- Phase 3 Thio-104 Set to Begin in Mid-2025; Potential Filing in 2026 for Early Full Approval

THOMSON REUTERS

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?

BRIEF-Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price To $11.2 Million - SEC Filing

Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price to $11.2 Million - SEC Filing

THOMSON REUTERS

Maia Biotechnology Announces Poster Presentation at Esmo's European Lung Cancer Congress 2025

THOMSON REUTERS

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

BRIEF-Maia Biotechnology Receives Usan Council Approval For “Ateganosine” As Nonproprietary Name For Anticancer Agent Thio

Maia Biotechnology Inc - to Retain Name Thio in Clinical Trial Designations

THOMSON REUTERS

Maia Biotechnology Receives Usan Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent Thio

THOMSON REUTERS

BRIEF-Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104

Maia Biotechnology Inc: Lans to Initiate a Phase 3 Pivotal Trial in 2025, Named Thio-104

THOMSON REUTERS

Maia Biotechnology Expects to Begin Enrolling Patients in Thio-104 in Second Half of 2025 in Select Countries in Asia, Europe, U.s

THOMSON REUTERS

Maia Biotechnology Plans to Begin Phase 3 Lung Cancer Trial of THIO-104 in H2

MT Newswires Live

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC study

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Maia Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAIA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAIA\",,,,,undefined,":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":2.1,"timestamp":1745524800000,"preClose":2.05,"halted":0,"volume":238477,"hourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.1,"latestTime":"19:56 EDT","volume":9569,"amount":19195.6969,"timestamp":1745538995317},"delay":0,"floatShares":25054078,"shares":29587314,"eps":-1.047624,"marketStatus":"Closed","change":0.05,"latestTime":"04-24 16:00:00 EDT","open":2.05,"high":2.1,"low":1.9,"amount":477013.4761638,"amplitude":0.097561,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.047624,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745568000000},"marketStatusCode":5,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":2.05,"preHourTrading":{"tag":"盘前","latestPrice":1.99,"preClose":2.05,"latestTime":"09:20 EDT","volume":3999,"amount":8049.4799268,"timestamp":1745500859610},"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.1,"latestTime":"19:56 EDT","volume":9569,"amount":19195.6969,"timestamp":1745538995317},"volumeRatio":0.631154},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAIA\",,,,,undefined,":{"symbol":"MAIA","floatShares":25054078,"roa":"-119.60%","roe":"-1131.02%","lyrEps":-1.047624,"volumeRatio":0.631154,"shares":29587314,"dividePrice":0,"high":2.1,"amplitude":0.097561,"preClose":2.05,"low":1.9,"week52Low":1.4,"pbRate":"17.09","week52High":5.99,"institutionHeld":0,"latestPrice":2.1,"eps":-1.047624,"divideRate":0,"volume":238477,"delay":0,"ttmEps":-1.047624,"open":2.05,"prevYearClose":1.98,"prevWeekClose":1.55,"prevMonthClose":1.53,"prevQuarterClose":1.53,"fiveDayClose":1.54,"twentyDayClose":1.65,"sixtyDayClose":1.86},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAIA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524911412","title":"BRIEF-MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2524911412","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524911412?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:36","pubTimestamp":1743514596,"startTime":"0","endTime":"0","summary":"BRIEF-MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated ApprovalApril 1 (Reuters) - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY- PHASE 2 TRIAL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2524811558","title":"Maia Biotechnology- Phase 3 Thio-104 Set to Begin in Mid-2025; Potential Filing in 2026 for Early Full Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2524811558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524811558?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:37","pubTimestamp":1743511036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF0ND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2524152021","title":"MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2524152021","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524152021?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:30","pubTimestamp":1743510600,"startTime":"0","endTime":"0","summary":"Lead compound THIO  is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery. Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104. Full Shareholder Letter available in Investors section of MAIA’s corporate website. CHICAGO, April 01, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2025 Shareholder Letter by CEO Vlad Vitoc, M.D. detailing the Company’s key milestones for 2025 including several clinical trials and regulatory pathways.\"MAIA continues to bring innovation to the biotech industry as one of the earliest pioneers of telomere targeting as a strategy for cancer treatment. Our lead candidate is THIO , the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery,\" states Dr. Vitoc at the opening of his shareholder letter. \"We are working on mult","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-ceo-details-anticipated-123000047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2523006315","title":"Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?","url":"https://stock-news.laohu8.com/highlight/detail?id=2523006315","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523006315?lang=en_us&edition=fundamental","pubTime":"2025-03-28 22:39","pubTimestamp":1743172757,"startTime":"0","endTime":"0","summary":"We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where MAIA Biotechnology, Inc.  stands against other cheapest stocks insiders are buying in March.After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday’s enthusiasm came from hopes of looser U.S. tariffs.Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers’ short-term outlook on income, business, and job conditions, reports CNBC.What are some of the cheapest stocks insiders have been buying this month so far?To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least two insiders had purchased shares in March. From there, we ranked the 10 stocks with the lowest average price per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-inc-maia-cheapest-143917054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2522356666","title":"BRIEF-Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price To $11.2 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522356666","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522356666?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:16","pubTimestamp":1743023790,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price To $11.2 Million - SEC FilingMarch 26  - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY INC - DECREASES MAXIMUM AGGREGATE OFFERING PRICE TO $11.2 MILLION - SEC FILINGSource text: [ID:n0001641172-25-000788]Further company coverage: MAIA.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2522356652","title":"Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price to $11.2 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522356652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522356652?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:15","pubTimestamp":1743023726,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2522907535","title":"Maia Biotechnology Announces Poster Presentation at Esmo's European Lung Cancer Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522907535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522907535?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:46","pubTimestamp":1742906760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA696Q5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2522007834","title":"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522007834","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522007834?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:46","pubTimestamp":1742906760,"startTime":"0","endTime":"0","summary":"Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer . CHICAGO, March 25, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025  taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology .\"We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,\" said Vlad Vitoc, M.D., CEO of MAIA. \"Our poster features our latest findings on cytokine Interleukin-6  as a potential predictive immune response biomarker for THIO sequenced with a checkpoint inhibitor. Predictive biomarkers can further illuminate THIO’s unique mechanisms of action which have shown exceptional efficacy in our Phase 2 clinical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-poster-presentation-124600460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAIA","LU0053666078.USD","BK4585","BK4139","BK4107","L","BK4588"],"gpt_icon":0},{"id":"2520452627","title":"MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug","url":"https://stock-news.laohu8.com/highlight/detail?id=2520452627","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520452627?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:20","pubTimestamp":1742476800,"startTime":"0","endTime":"0","summary":"Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance. CHICAGO, March 20, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn-Schmiedeberg's Archives of Pharmacology.Naunyn–Schmiedeberg’s Archives of Pharmacology, founded in 1873, is the oldest existing pharmacological journal and a dedicated platform for new and significant information on drug action and toxicity of chemical compounds. The peer-reviewed scientific journal covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in neuropharmacology and cardiovascular pharmacology and those describing drug actions at the cellular, biochemical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-publication-peer-132000569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MAIA","BK4585","BK4588","LU0053666078.USD","L","BK4107"],"gpt_icon":0},{"id":"2520549061","title":"BRIEF-Maia Biotechnology Receives Usan Council Approval For “Ateganosine” As Nonproprietary Name For Anticancer Agent Thio","url":"https://stock-news.laohu8.com/highlight/detail?id=2520549061","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520549061?lang=en_us&edition=fundamental","pubTime":"2025-03-20 00:14","pubTimestamp":1742400899,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Receives Usan Council Approval For “Ateganosine” As Nonproprietary Name For Anticancer Agent ThioMarch 19  - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY RECEIVES USAN COUNCIL APPROVAL FOR “ATEGANOSINE” AS NONPROPRIETARY NAME FOR ANTICANCER AGENT THIOMAIA BIOTECHNOLOGY INC - TO RETAIN NAME THIO IN CLINICAL TRIAL DESIGNATIONS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2520130206","title":"Maia Biotechnology Inc - to Retain Name Thio in Clinical Trial Designations","url":"https://stock-news.laohu8.com/highlight/detail?id=2520130206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520130206?lang=en_us&edition=fundamental","pubTime":"2025-03-19 23:01","pubTimestamp":1742396489,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20GC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2520130205","title":"Maia Biotechnology Receives Usan Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent Thio","url":"https://stock-news.laohu8.com/highlight/detail?id=2520130205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520130205?lang=en_us&edition=fundamental","pubTime":"2025-03-19 23:01","pubTimestamp":1742396489,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2514540763","title":"BRIEF-Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2514540763","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514540763?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:31","pubTimestamp":1740699071,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104Feb 27  - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY INC: LANS TO INITIATE A PHASE 3 PIVOTAL TRIAL IN 2025, NAMED THIO-104MAIA BIOTECHNOLOGY EXPECTS TO BEGIN ENROLLING PATIENTS IN THIO-104 IN SECOND HALF OF 2025 IN SELECT COUNTRIES IN ASIA, EUROPE, U.SSource text: [ID:n0001493152-25-008540]Further company coverage: MAIA.A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2514548103","title":"Maia Biotechnology Inc: Lans to Initiate a Phase 3 Pivotal Trial in 2025, Named Thio-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2514548103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514548103?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:11","pubTimestamp":1740697878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2514354824","title":"Maia Biotechnology Expects to Begin Enrolling Patients in Thio-104 in Second Half of 2025 in Select Countries in Asia, Europe, U.s","url":"https://stock-news.laohu8.com/highlight/detail?id=2514354824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514354824?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:11","pubTimestamp":1740697878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2EJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2514238413","title":"Maia Biotechnology Plans to Begin Phase 3 Lung Cancer Trial of THIO-104 in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514238413?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:54","pubTimestamp":1740671679,"startTime":"0","endTime":"0","summary":"Maia Biotechnology  plans to start enrollment of certain patients resistant to checkpoint inhibitors and chemotherapy in a phase 3 study of THIO-104 for non-small lung cancer in H2.The trial will evaluate the efficacy of THIO-104 administered in sequence with a checkpoint inhibitor to improve the overall survival of patients whose cancer has continued to grow after two previous lines of systemic treatment, the company said Thursday in a statement.The study will enroll up to 300 patients in Asia, Europe and the US to compare the treatment with chemotherapy in 1-to-1 randomization, the company said.Price: 1.85, Change: +0.01, Percent Change: +0.54","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2514800734","title":"MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2514800734","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514800734?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:51","pubTimestamp":1740664260,"startTime":"0","endTime":"0","summary":"CHICAGO, February 27, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced plans to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor  in third-line non-small cell lung cancer  patients who are resistant to checkpoint inhibitors and chemotherapy. The multicenter, open-label, pivotal Phase 3 trial is designed to provide a direct comparison to chemotherapy in a 1:1 randomization of up to 300 patients.\"THIO has consistently and substantially outperformed standard treatment options in our THIO-101 Phase 2 trial to date. THIO-104 will give us direct comparative data from a randomized study in patients in third line of treatment,\" said Vlad Vitoc, M.D., CEO of MAIA. \"We expect that the results from this study will further illuminate THIO’s unmatched benefits for advanced stage NSCLC patients.MAIA is a targeted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-initiate-phase-3-135100127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","CPI","MAIA","AEIS","BK4157","IE00B7SZL793.SGD","IE00B19Z4B17.USD","L","IE0031619046.USD","LU0053666078.USD","IE00B66KJ199.SGD","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2514378855","title":"MAIA Biotech  announces trial design to expand THIO-101 Phase 2 NSCLC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514378855?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:12","pubTimestamp":1740579174,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer NSCLC . ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotech-announces-trial-design-to-expand-thio-101-phase-2-nsclc-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotech-announces-trial-design-to-expand-thio-101-phase-2-nsclc-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2514853387","title":"MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853387","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853387?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:47","pubTimestamp":1740577620,"startTime":"0","endTime":"0","summary":"Expansion study to enroll patients in the U.S. and select countries in Europe and Asia. CHICAGO, February 26, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer . Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates  in advanced NSCLC patients receiving third line  therapy who were resistant to previous checkpoint inhibitor treatments  and chemotherapy.MAIA recently announced an amended clinical supply agreement with Regeneron to include the expansion portion of THIO-101. Under terms of the amended agreement, MAIA continues to sponsor THIO-101 and Regeneron will provide Libtayo for the treatment of all patients including the additional patients in the expansion and potentially, the registration studies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-design-expansion-134700870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1059921491.USD","IE0031619046.USD","IE00B7SZL793.SGD","IE0002270589.USD","AEIS","IE00B66KJ199.SGD","BK4585","BK4157","LU0058720904.USD","LU0289739699.SGD","BK4107","IE00B19Z3B42.SGD","BK4588","BK4196","MAIA","ORR","IE00BSNM7G36.USD","IE00B19Z3581.USD","IE00B19Z4B17.USD","BK4139","LU0868494617.USD","BK4097","CI","OS","L","LU0053666078.USD","LU1261432733.SGD","CPI"],"gpt_icon":0},{"id":"2514070933","title":"Maia Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514070933?lang=en_us&edition=fundamental","pubTime":"2025-02-25 05:30","pubTimestamp":1740432600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA7MWZLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAIA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1677038400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAIA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAIA","date":"2025-04-23","current":-2.379234,"percent":0.408748,"low":-5.555213,"twenty":-2.815256,"median":-2.182973,"eighty":-1.604833,"high":-0.77644,"avg":-2.231486,"sd":0.717112,"marketCap":55328277},"quantilePoints":[{"date":"2022-07-29","current":-4.130799,"twenty":-3.74477,"median":-3.33193,"eighty":-3.032982,"marketCap":61688243},{"date":"2022-08-05","current":-3.418592,"twenty":-4.327368,"median":-3.717719,"eighty":-3.321732,"marketCap":51052339},{"date":"2022-08-12","current":-3.539667,"twenty":-3.942776,"median":-3.513542,"eighty":-3.113768,"marketCap":52860442},{"date":"2022-08-19","current":-2.813217,"twenty":-3.757603,"median":-3.418592,"eighty":-3.057447,"marketCap":42011820},{"date":"2022-08-26","current":-2.813564,"twenty":-3.645074,"median":-3.16932,"eighty":-3.031815,"marketCap":41665794},{"date":"2022-09-02","current":-3.160645,"twenty":-3.562458,"median":-3.149236,"eighty":-2.973073,"marketCap":46805669},{"date":"2022-09-09","current":-3.035105,"twenty":-3.531121,"median":-3.079413,"eighty":-2.987843,"marketCap":44946565},{"date":"2022-09-16","current":-2.628947,"twenty":-3.505948,"median":-3.054305,"eighty":-2.874118,"marketCap":38931818},{"date":"2022-09-23","current":-2.400022,"twenty":-3.459888,"median":-3.035105,"eighty":-2.808995,"marketCap":35541688},{"date":"2022-09-30","current":-2.436946,"twenty":-3.337714,"median":-3.018069,"eighty":-2.628947,"marketCap":36088483},{"date":"2022-10-07","current":-2.481254,"twenty":-3.200415,"median":-2.976027,"eighty":-2.544762,"marketCap":36744637},{"date":"2022-10-14","current":-2.429561,"twenty":-3.170744,"median":-2.946489,"eighty":-2.506362,"marketCap":35979124},{"date":"2022-10-21","current":-2.326175,"twenty":-3.161577,"median":-2.817793,"eighty":-2.443001,"marketCap":34448097},{"date":"2022-10-28","current":-2.392637,"twenty":-3.156081,"median":-2.809698,"eighty":-2.436946,"marketCap":35432328},{"date":"2022-11-04","current":-2.673255,"twenty":-3.130168,"median":-2.80618,"eighty":-2.436946,"marketCap":39587972},{"date":"2022-11-11","current":-2.861595,"twenty":-3.092705,"median":-2.80618,"eighty":-2.443001,"marketCap":41539705},{"date":"2022-11-18","current":-2.59391,"twenty":-3.074979,"median":-2.80618,"eighty":-2.45489,"marketCap":37653909},{"date":"2022-11-25","current":-2.639153,"twenty":-3.06641,"median":-2.741401,"eighty":-2.463531,"marketCap":38310664},{"date":"2022-12-02","current":-2.782421,"twenty":-3.056964,"median":-2.74683,"eighty":-2.481254,"marketCap":40390385},{"date":"2022-12-09","current":-2.639153,"twenty":-3.048124,"median":-2.714557,"eighty":-2.485685,"marketCap":38310664},{"date":"2022-12-16","current":-2.571289,"twenty":-3.039919,"median":-2.704828,"eighty":-2.491357,"marketCap":37325532},{"date":"2022-12-23","current":-2.526046,"twenty":-3.035105,"median":-2.684395,"eighty":-2.489852,"marketCap":36668778},{"date":"2022-12-30","current":-2.646693,"twenty":-3.035105,"median":-2.669314,"eighty":-2.488344,"marketCap":38420123},{"date":"2023-01-06","current":-2.646693,"twenty":-3.028524,"median":-2.669314,"eighty":-2.494376,"marketCap":38420123},{"date":"2023-01-13","current":-3.008634,"twenty":-3.036309,"median":-2.678825,"eighty":-2.495884,"marketCap":43674156},{"date":"2023-01-20","current":-3.649345,"twenty":-3.053419,"median":-2.693672,"eighty":-2.500398,"marketCap":52974891},{"date":"2023-01-27","current":-3.381885,"twenty":-3.088275,"median":-2.710179,"eighty":-2.507838,"marketCap":49092379},{"date":"2023-02-03","current":-3.566626,"twenty":-3.137263,"median":-2.727137,"eighty":-2.510896,"marketCap":51774125},{"date":"2023-02-10","current":-3.332873,"twenty":-3.167896,"median":-2.752259,"eighty":-2.519723,"marketCap":48380895},{"date":"2023-02-17","current":-3.415817,"twenty":-3.245403,"median":-2.79807,"eighty":-2.525852,"marketCap":49584945},{"date":"2023-02-24","current":-3.566626,"twenty":-3.3193,"median":-2.80618,"eighty":-2.527554,"marketCap":51774125},{"date":"2023-03-03","current":-3.4686,"twenty":-3.350216,"median":-2.813564,"eighty":-2.531068,"marketCap":50351158},{"date":"2023-03-10","current":-3.016174,"twenty":-3.350216,"median":-2.827663,"eighty":-2.542251,"marketCap":43783616},{"date":"2023-03-17","current":-2.473263,"twenty":-3.346445,"median":-2.827663,"eighty":-2.542251,"marketCap":35902565},{"date":"2023-03-24","current":-2.399976,"twenty":-3.342675,"median":-2.81339,"eighty":-2.516804,"marketCap":38927270},{"date":"2023-03-31","current":-2.345739,"twenty":-3.337397,"median":-2.80618,"eighty":-2.495884,"marketCap":38047557},{"date":"2023-04-06","current":-2.284723,"twenty":-3.326087,"median":-2.805042,"eighty":-2.481254,"marketCap":37057881},{"date":"2023-04-14","current":-2.447433,"twenty":-3.292155,"median":-2.76734,"eighty":-2.461933,"marketCap":39697018},{"date":"2023-04-21","current":-2.393197,"twenty":-3.261993,"median":-2.739718,"eighty":-2.455007,"marketCap":38817306},{"date":"2023-04-28","current":-1.958672,"twenty":-3.24842,"median":-2.712368,"eighty":-2.44201,"marketCap":31769373},{"date":"2023-05-05","current":-2.318612,"twenty":-3.242387,"median":-2.695409,"eighty":-2.436946,"marketCap":37607553},{"date":"2023-05-12","current":-2.109365,"twenty":-3.242387,"median":-2.678825,"eighty":-2.414792,"marketCap":34746108},{"date":"2023-05-19","current":-1.988788,"twenty":-3.237189,"median":-2.669314,"eighty":-2.399985,"marketCap":33656034},{"date":"2023-05-26","current":-1.827752,"twenty":-3.208406,"median":-2.654233,"eighty":-2.392749,"marketCap":30930849},{"date":"2023-06-02","current":-2.069306,"twenty":-3.176442,"median":-2.646693,"eighty":-2.379637,"marketCap":35018627},{"date":"2023-06-09","current":-1.988788,"twenty":-3.162198,"median":-2.639153,"eighty":-2.33896,"marketCap":33656034},{"date":"2023-06-16","current":-1.851908,"twenty":-3.160645,"median":-2.635382,"eighty":-2.318791,"marketCap":31339627},{"date":"2023-06-23","current":-1.763338,"twenty":-3.153651,"median":-2.628947,"eighty":-2.307373,"marketCap":29840775},{"date":"2023-06-30","current":-1.731131,"twenty":-3.150302,"median":-2.609948,"eighty":-2.28744,"marketCap":29295738},{"date":"2023-07-07","current":-1.779442,"twenty":-3.141254,"median":-2.59768,"eighty":-2.242232,"marketCap":30113294},{"date":"2023-07-14","current":-1.755286,"twenty":-3.123249,"median":-2.586369,"eighty":-2.20532,"marketCap":29704516},{"date":"2023-07-21","current":-1.851908,"twenty":-3.111184,"median":-2.578041,"eighty":-2.067676,"marketCap":31339627},{"date":"2023-07-28","current":-1.859959,"twenty":-3.104623,"median":-2.56987,"eighty":-2.008112,"marketCap":31475886},{"date":"2023-08-04","current":-1.715028,"twenty":-3.097572,"median":-2.563748,"eighty":-1.974295,"marketCap":29023220},{"date":"2023-08-11","current":-1.557401,"twenty":-3.086713,"median":-2.556208,"eighty":-1.943698,"marketCap":28252239},{"date":"2023-08-18","current":-1.369309,"twenty":-3.075231,"median":-2.531381,"eighty":-1.90827,"marketCap":24840133},{"date":"2023-08-25","current":-1.437022,"twenty":-3.068706,"median":-2.525562,"eighty":-1.887815,"marketCap":26068491},{"date":"2023-09-01","current":-1.316644,"twenty":-3.064492,"median":-2.5071,"eighty":-1.866401,"marketCap":23884743},{"date":"2023-09-08","current":-1.32732,"twenty":-3.056964,"median":-2.495884,"eighty":-1.852819,"marketCap":24078428},{"date":"2023-09-15","current":-1.319779,"twenty":-3.048124,"median":-2.488344,"eighty":-1.851908,"marketCap":23941618},{"date":"2023-09-22","current":-1.161405,"twenty":-3.039919,"median":-2.477259,"eighty":-1.830989,"marketCap":21068624},{"date":"2023-09-29","current":-1.357487,"twenty":-3.035105,"median":-2.458182,"eighty":-1.797155,"marketCap":24625665},{"date":"2023-10-06","current":-1.89294,"twenty":-3.03346,"median":-2.451363,"eighty":-1.795545,"marketCap":34339121},{"date":"2023-10-13","current":-1.696859,"twenty":-3.026246,"median":-2.440654,"eighty":-1.781052,"marketCap":30782081},{"date":"2023-10-20","current":-1.772274,"twenty":-3.023715,"median":-2.436946,"eighty":-1.772274,"marketCap":32150173},{"date":"2023-10-27","current":-1.402736,"twenty":-3.020699,"median":-2.436946,"eighty":-1.772274,"marketCap":25446520},{"date":"2023-11-03","current":-1.538485,"twenty":-3.016174,"median":-2.424938,"eighty":-1.763338,"marketCap":27909087},{"date":"2023-11-10","current":-1.563529,"twenty":-3.013408,"median":-2.414792,"eighty":-1.758507,"marketCap":28319514},{"date":"2023-11-17","current":-1.098625,"twenty":-3.009008,"median":-2.400022,"eighty":-1.737573,"marketCap":19898915},{"date":"2023-11-24","current":-1.0945,"twenty":-3.00802,"median":-2.398918,"eighty":-1.715028,"marketCap":19824192},{"date":"2023-12-01","current":-0.93547,"twenty":-3.003917,"median":-2.393197,"eighty":-1.697272,"marketCap":16943754},{"date":"2023-12-08","current":-0.853009,"twenty":-2.993064,"median":-2.385536,"eighty":-1.662077,"marketCap":15450179},{"date":"2023-12-15","current":-0.830323,"twenty":-2.97455,"median":-2.366078,"eighty":-1.603306,"marketCap":15039276},{"date":"2023-12-22","current":-0.963534,"twenty":-2.967166,"median":-2.34235,"eighty":-1.566156,"marketCap":17452066},{"date":"2023-12-29","current":-1.159983,"twenty":-2.962735,"median":-2.332248,"eighty":-1.560368,"marketCap":21010254},{"date":"2024-01-05","current":-1.113209,"twenty":-2.959095,"median":-2.329178,"eighty":-1.540033,"marketCap":20163067},{"date":"2024-01-12","current":-1.319013,"twenty":-2.946198,"median":-2.318612,"eighty":-1.505189,"marketCap":23890693},{"date":"2024-01-19","current":-1.178692,"twenty":-2.917694,"median":-2.307373,"eighty":-1.461419,"marketCap":21349130},{"date":"2024-01-26","current":-1.262884,"twenty":-2.860841,"median":-2.292944,"eighty":-1.43018,"marketCap":22874067},{"date":"2024-02-02","current":-1.449978,"twenty":-2.853404,"median":-2.250825,"eighty":-1.422652,"marketCap":26262818},{"date":"2024-02-09","current":-1.337722,"twenty":-2.835718,"median":-2.238161,"eighty":-1.406928,"marketCap":24229568},{"date":"2024-02-16","current":-1.472372,"twenty":-2.835615,"median":-2.225173,"eighty":-1.406928,"marketCap":26668418},{"date":"2024-02-23","current":-1.37859,"twenty":-2.835204,"median":-2.173979,"eighty":-1.403205,"marketCap":24969793},{"date":"2024-03-01","current":-1.228539,"twenty":-2.828334,"median":-2.067947,"eighty":-1.384495,"marketCap":22251992},{"date":"2024-03-08","current":-1.312943,"twenty":-2.827663,"median":-2.013443,"eighty":-1.37859,"marketCap":23780755},{"date":"2024-03-15","current":-1.228539,"twenty":-2.827663,"median":-1.99684,"eighty":-1.369309,"marketCap":22251992},{"date":"2024-03-22","current":-1.819364,"twenty":-2.817793,"median":-1.988788,"eighty":-1.369309,"marketCap":32953332},{"date":"2024-03-28","current":-2.508838,"twenty":-2.81441,"median":-1.988788,"eighty":-1.373975,"marketCap":49607008},{"date":"2024-04-05","current":-2.225582,"twenty":-2.813286,"median":-2.013193,"eighty":-1.375141,"marketCap":44006217},{"date":"2024-04-12","current":-2.458256,"twenty":-2.807587,"median":-2.066589,"eighty":-1.376495,"marketCap":48606867},{"date":"2024-04-19","current":-2.040149,"twenty":-2.80618,"median":-2.065155,"eighty":-1.378239,"marketCap":40339679},{"date":"2024-04-26","current":-2.789592,"twenty":-2.80618,"median":-2.083954,"eighty":-1.37859,"marketCap":55158336},{"date":"2024-05-03","current":-3.278811,"twenty":-2.81441,"median":-2.154257,"eighty":-1.383204,"marketCap":64831627},{"date":"2024-05-10","current":-3.008179,"twenty":-2.829708,"median":-2.225173,"eighty":-1.384467,"marketCap":59480445},{"date":"2024-05-17","current":-2.706777,"twenty":-2.835307,"median":-2.225893,"eighty":-1.384495,"marketCap":64214183},{"date":"2024-05-24","current":-3.507054,"twenty":-2.863599,"median":-2.234604,"eighty":-1.387273,"marketCap":83199537},{"date":"2024-05-31","current":-4.040936,"twenty":-2.958014,"median":-2.241717,"eighty":-1.392304,"marketCap":95865084},{"date":"2024-06-07","current":-3.056015,"twenty":-2.984545,"median":-2.267774,"eighty":-1.39972,"marketCap":72499334},{"date":"2024-06-14","current":-3.488644,"twenty":-3.008452,"median":-2.292944,"eighty":-1.402924,"marketCap":82762794},{"date":"2024-06-21","current":-3.157269,"twenty":-3.016174,"median":-2.307373,"eighty":-1.403205,"marketCap":74901421},{"date":"2024-06-28","current":-3.06522,"twenty":-3.024981,"median":-2.311144,"eighty":-1.403205,"marketCap":72717706},{"date":"2024-07-05","current":-3.12045,"twenty":-3.037686,"median":-2.318701,"eighty":-1.404613,"marketCap":74027935},{"date":"2024-07-12","current":-3.516259,"twenty":-3.053559,"median":-2.33218,"eighty":-1.406806,"marketCap":83417909},{"date":"2024-07-15","current":-3.359776,"twenty":-3.057103,"median":-2.332214,"eighty":-1.406847,"marketCap":79705593},{"date":"2024-08-02","current":-2.853508,"twenty":-3.056559,"median":-2.332248,"eighty":-1.406887,"marketCap":67695161},{"date":"2024-08-09","current":-2.448494,"twenty":-3.051102,"median":-2.34235,"eighty":-1.406928,"marketCap":58086816},{"date":"2024-08-16","current":-2.426555,"twenty":-3.049827,"median":-2.33896,"eighty":-1.409608,"marketCap":68135554},{"date":"2024-08-23","current":-2.554268,"twenty":-3.042861,"median":-2.346358,"eighty":-1.412104,"marketCap":71721636},{"date":"2024-08-30","current":-2.383983,"twenty":-3.039749,"median":-2.352417,"eighty":-1.420092,"marketCap":66940193},{"date":"2024-09-06","current":-2.681981,"twenty":-3.036825,"median":-2.358441,"eighty":-1.424007,"marketCap":75307717},{"date":"2024-09-13","current":-2.767124,"twenty":-3.035105,"median":-2.377326,"eighty":-1.427844,"marketCap":77698439},{"date":"2024-09-20","current":-2.426555,"twenty":-3.030169,"median":-2.383983,"eighty":-1.429499,"marketCap":68135554},{"date":"2024-09-27","current":-2.222213,"twenty":-3.024981,"median":-2.383983,"eighty":-1.430561,"marketCap":62397823},{"date":"2024-10-04","current":-2.213699,"twenty":-3.01919,"median":-2.379637,"eighty":-1.432249,"marketCap":62158751},{"date":"2024-10-11","current":-2.247756,"twenty":-3.016174,"median":-2.371702,"eighty":-1.435374,"marketCap":63115039},{"date":"2024-10-18","current":-2.141328,"twenty":-3.012024,"median":-2.358441,"eighty":-1.437022,"marketCap":60126638},{"date":"2024-10-25","current":-2.188156,"twenty":-3.008884,"median":-2.346358,"eighty":-1.441989,"marketCap":61441534},{"date":"2024-10-31","current":-2.389927,"twenty":-3.008452,"median":-2.345739,"eighty":-1.447172,"marketCap":67107079},{"date":"2024-11-08","current":-2.83377,"twenty":-3.007134,"median":-2.34725,"eighty":-1.453828,"marketCap":79569822},{"date":"2024-11-15","current":-1.968024,"twenty":-3.002269,"median":-2.346358,"eighty":-1.460958,"marketCap":51049313},{"date":"2024-11-22","current":-2.076001,"twenty":-2.988805,"median":-2.341497,"eighty":-1.465271,"marketCap":53850185},{"date":"2024-11-29","current":-2.158258,"twenty":-2.975456,"median":-2.338036,"eighty":-1.469425,"marketCap":55983872},{"date":"2024-12-06","current":-1.933643,"twenty":-2.972266,"median":-2.332214,"eighty":-1.472826,"marketCap":50157496},{"date":"2024-12-13","current":-1.96294,"twenty":-2.967505,"median":-2.321643,"eighty":-1.479063,"marketCap":50917458},{"date":"2024-12-20","current":-1.992238,"twenty":-2.962612,"median":-2.316763,"eighty":-1.498022,"marketCap":51677420},{"date":"2024-12-27","current":-1.992238,"twenty":-2.961258,"median":-2.307373,"eighty":-1.503103,"marketCap":51677420},{"date":"2025-01-03","current":-2.041067,"twenty":-2.956932,"median":-2.307355,"eighty":-1.507276,"marketCap":52944024},{"date":"2025-01-10","current":-2.080131,"twenty":-2.941372,"median":-2.303098,"eighty":-1.515197,"marketCap":53957306},{"date":"2025-01-17","current":-1.972706,"twenty":-2.899372,"median":-2.296637,"eighty":-1.531004,"marketCap":51170779},{"date":"2025-01-24","current":-1.933643,"twenty":-2.87533,"median":-2.284723,"eighty":-1.538485,"marketCap":50157496},{"date":"2025-01-31","current":-1.875661,"twenty":-2.867606,"median":-2.264784,"eighty":-1.540033,"marketCap":48653485},{"date":"2025-02-07","current":-1.996671,"twenty":-2.860087,"median":-2.25627,"eighty":-1.544371,"marketCap":51792420},{"date":"2025-02-14","current":-1.885745,"twenty":-2.856098,"median":-2.247756,"eighty":-1.551399,"marketCap":48915063},{"date":"2025-02-21","current":-1.915998,"twenty":-2.84995,"median":-2.243914,"eighty":-1.558143,"marketCap":49699797},{"date":"2025-02-28","current":-1.986587,"twenty":-2.835718,"median":-2.237919,"eighty":-1.561594,"marketCap":51530842},{"date":"2025-03-07","current":-1.854501,"twenty":-2.835615,"median":-2.232622,"eighty":-1.563808,"marketCap":48104595},{"date":"2025-03-14","current":-1.703553,"twenty":-2.834917,"median":-2.225582,"eighty":-1.566156,"marketCap":44189105},{"date":"2025-03-21","current":-1.897628,"twenty":-2.832683,"median":-2.223693,"eighty":-1.572339,"marketCap":49223306},{"date":"2025-03-28","current":-2.073878,"twenty":-2.8282,"median":-2.216853,"eighty":-1.577368,"marketCap":48227321},{"date":"2025-04-04","current":-2.022985,"twenty":-2.827663,"median":-2.202461,"eighty":-1.578876,"marketCap":47043829},{"date":"2025-04-11","current":-1.857584,"twenty":-2.825689,"median":-2.188156,"eighty":-1.588437,"marketCap":43197478},{"date":"2025-04-17","current":-1.959369,"twenty":-2.817793,"median":-2.17779,"eighty":-1.602543,"marketCap":45564463},{"date":"2025-04-23","current":-2.379234,"twenty":-2.815256,"median":-2.182973,"eighty":-1.604833,"marketCap":55328277}],"updateTime":1745517690606}}}